Cancer-Pancreatic
| Title: | Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Treatment in Patients With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen |
| Description: | This is an open-label, multi-center, randomized, Phase 3 study designed to compare the efficacy and safety of AM0010 in combination with FOLFOX versus FOLFOX alone in patients with metastatic adenocarcinoma of the pancreas who have progressed on one prior gemcitabine containing regimen. |
| Drug/Procedure: | AM0010; FOLFOX |
| NCT Number: | 02923921 |
| Notes: | Phase 3 |
| Start Date: | 4/24/17 |
| Status: | Recruiting |
| Principal Name: | Kerry Pulver, MD |
| Contact Name: | Tina Schied, CCRC |
| Phone: | (208)367-3481 |